Correction: Effect of Oral Snus and Medicinal Nicotine in Smokers on Toxicant Exposure and Withdrawal Symptoms: A Feasibility Study

In this article (1), which was published in the January 2011 issue of Cancer Epidemiology, Biomarkers & Prevention, the following modifications were requested by the authors. The corrected data include the following: (i) Table 1 and Subjects portion of results section: Baseline FTND score was 5.2 ± 1.8 for those receiving Camel Snus, 5.3 ± 1.9 for those receiving medicinal nicotine, and 5.5 ± 1.7 for those receiving Taboka (P = 0.78). For those who completed the study, FTND scores were 5.4 ± 1.9 for those receiving Camel Snus, 5.1 ± 2.0 for those receiving medicinal nicotine, and 5.2 ± 2.0 for those receiving Taboka. For those who did not complete the study, FTND scores were 5.0 ± 1.6, 5.6 ± 1.8, and 6.0 ± 1.1, respectively; (ii) Outcome Measures portion of Methods section: The items in the withdrawal symptoms scale used were craving, irritability/frustration/anger, anxiety, difficulty concentrating, restlessness, increased appetite/weight gain, depressed or sad mood, and insomnia/sleep problems; (iii) Table 1: The average age reported for becoming a regular smoker in the Taboka group was based on 51 subjects; and (iv) Statistical Analysis portion of the Methods section: Each repeated-measures model included the treatment effect, a visit effect, the interaction between treatment and visit, and the between-subject error and within-subject error terms.